e24044 Background: Sweet syndrome (SS) or acute febrile neutrophilic dermatosis typically present as patients with pyrexia, neutrophilia and rash with dermal neutrophilic dominance on biopsy. While the association of SS with malignancy is well-documented, the connection of sweet syndrome and solid tumors especially breast cancers is not explored enough. It is important to understand these associations better understand the disease course of SS in the setting of breast cancer. We aim to examine the different triggers, subtypes of breast cancer associated with SS, and differences in presentation and resolution time. Methods: A literature review from 1/1950-11/2023 was conducted for co-existing diagnoses of BC and SS in the PubMed Database. Search terms included Sweet Syndrome or Acute febrile neutrophilic dermatosis with Breast Cancer with subtypes. Key outcomes included: trigger identification, breast cancer subtypes, and treatment options. Findings were analyzed via a thematic lens. Results: A total of 34 cases of female BC patients with SS were identified with triggers divided into subtypes of surgery (47%), medication (20%), paraneoplastic (20%), and radiation therapy (11%). Depending on the trigger, average time to presentation varied with drug-triggered being the shortest (3.3 months) followed by radiation (8.5 months) while surgery (50 months) and paraneoplastic- associated (57 months) had similar presentation times. Although the time to presentation time for paraneoplastic-associated SS was the longest, 50% of these cases were associated with underlying progression of cancer. Regarding treatment and resolution time, 26 cases of SS resolved after treatment with treatment mainstay including oral (65%) and topical (12%) steroids. Analyzing triggers specific treatment outcomes, drug (2.7 days) and radiation-induced SS (7 days) had shorter average resolution times while paraneoplastic- associated (10.5 days) and surgery-associated SS (18.5 days) had longer resolution times. 5 cases that documented initial relapse or recurrence of SS after initial treatment were associated with paraneoplastic –induced sweet syndrome. On further analysis, among the 15 cases mentioned the BC type associated with SS- the most common breast cancer subtype was invasive ductal carcinoma of the breast (47%) followed by metastatic carcinoma (20%), adenocarcinoma (13%) and invasive lobular carcinoma (6%), canalicular breast carcinoma (6%) and unspecified malignant tumor of the breast (6%) regardless of the trigger mentioned. Conclusions: Oncologists should always consider SS on the differential for BC patients presenting with fever and rash given the varied presentation times depending on type of trigger. Treatment should be started promptly and continued for an adequate amount of time depending on the trigger to better mitigate complications in breast cancer patients.